Cancer screening continues to evolve, and multi-cancer early detection (MCED) testing is emerging as a promising advancement in the early detection landscape. Join us September 16 at 12:00 pm for an informative webinar to introduce Cancerguard™, a multi-biomarker, blood-based MCED test designed to detect signals associated with multiple cancers from a single blood draw. Participants will gain an understanding of the science behind MCED technology, review current clinical evidence, and explore how these innovative tests may complement existing cancer screening approaches. The session will also examine the potential role of MCED testing in expanding opportunities for earlier cancer detection and improved patient outcomes.
Exploring the Future of Cancer Screening: Multi-Cancer Early Detection Testing
